ACKR3
ACKR3 (Atypical chemokine receptor 3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Ovarian cancer, Colorectal cancer, Skin cancer and 1 more.
Overview
Atypical chemokine receptor that controls chemokine levels and localisation via high-affinity chemokine binding that is uncoupled from classic ligand-driven signal transduction cascades, resulting instead in chemokine sequestration, degradation, or transcytosis. Also known as interceptor (internalising receptor) or chemokine-scavenging receptor or chemokine decoy receptor. Acts as a receptor for chemokines CXCL11 and CXCL12/SDF1.
Open Targets scores its association with cancer at 0.68 (direct and indirect evidence; datatypes literature 0.99, animal model 0.63, genetic association 0.45, somatic mutation 0.96). IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Ovarian Epithelial Tumour.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · ACKR3 (Atypical chemokine receptor 3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Ovarian cancer, Colorectal cancer, Skin cancer and 1 more.
- 1 · What it is
ACKR3 (Atypical chemokine receptor 3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Ovarian cancer, Colorectal cancer, Skin cancer and 1 more.
- 2 · What goes wrong in cancer
Atypical chemokine receptor that controls chemokine levels and localisation via high-affinity chemokine binding that is uncoupled from classic ligand-driven signal transduction cascades, resulting instead in chemokine sequestration, degradation, or transcytosis.
- 3 · How drugs use it
No product in this corpus aims at ACKR3 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:23692 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P25106 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000144476 (association with cancer (MONDO_0004992) 0.68; per-cancer scores at or above 0.5: colorectal cancer 0.54, melanoma 0.52, skin cancer 0.52 (GraphQL API, CC0)); IntOGen ACKR3 (driver in 1 cohort (Act 1, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Atypical chemokine receptor that controls chemokine levels and localisation via high-affinity chemokine binding that is uncoupled from classic ligand-driven signal transduction cascades, resulting instead in chemokine sequestration, degradation, or transcytosis. Also known as interceptor (internalising receptor) or chemokine-scavenging receptor or chemokine decoy receptor. Acts as a receptor for chemokines CXCL11 and CXCL12/SDF1. Chemokine binding does not activate G protein-mediated signal transduction but instead induces beta-arrestin recruitment, leading to ligand internalisation and activation of MAPK signalling pathway. Required for regulation of CXCR4 protein levels in migrating interneurons, thereby adapting their chemokine responsiveness. In glioma cells, transduces signals via MEK/ERK pathway, mediating resistance to apoptosis. Location: Cell membrane; Early endosome; Recycling endosome (UniProt). Locus 2q37.3 (HGNC).
- Ovarian cancer: IntOGen driver in 1 cohort (OVT)
- Colorectal cancer: Open Targets association 0.54 with colorectal cancer (MONDO_0005575)
- Skin cancer: Open Targets association 0.52 with skin cancer (MONDO_0002898)
- Melanoma: Open Targets association 0.52 with melanoma (MONDO_0005105)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"ACKR3" OR ABSTRACT:"ACKR3" OR TITLE:"atypical chemokine receptor 3" OR ABSTRACT:"atypical chemokine receptor 3" OR TITLE:"Atypical chemokine receptor 3" OR ABSTRACT:"Atypical chemokine receptor 3" OR TITLE:"RDC1" OR ABSTRACT:"RDC1" OR TITLE:"GPR159" OR ABSTRACT:"GPR159" OR TITLE:"CMKOR1" OR ABSTRACT:"CMKOR1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ACKR3, not a curated reading list.